Loading clinical trials...

UNKNOWNPHASE4

Ocular Allergy Treatment Practical Impact Trial

To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)

NCT01808768•Starx Research Center, LLC

View on ClinicalTrials.gov

Summary

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Detailed Description

To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens
•2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.
•3. have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.
•4. Are willing/able to follow instructions from the study investigator and his/her study staff.
•5. Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.
•\-

Exclusion Criteria

•1. Active ocular infection;
•2. History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
•3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.
•4. History of unstable, or uncontrolled disease of any nature.
•5. Pregnancy or lactation;
•6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -

Locations (2)

STARx Research Center

Edison, New Jersey, United States

STARx

Springfield, New Jersey, United States

Key Dates

Start Date

April 1, 2013

Primary Completion Date

October 1, 2013

Completion Date

November 1, 2013

Last Updated

May 30, 2013

Enrollment

ESTIMATED participants

Conditions

Allergic ConjunctivitisRhinoconjunctivitis

Interventions

Alcaftadine

DRUG

Contacts

Jayesh Kanuga, MD

CONTACT

732-906-1747 jkanuga@gmail.com

Erika Julca, LPN,CRC

CONTACT

732-906-1747 ejulca1@gmail.com

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990

Rhinitis, AllergicRhinoconjunctivitis+1 more

View study

RECRUITINGPHASE4

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT06778213

Allergic Rhinoconjunctivitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ocular Allergy Treatment Practical Impact Trial

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

Tyrosine Allergoid Paediatric and Adult Study

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

Study of BLU-808 in Allergic Rhinoconjunctivitis